FDA Device Intelligence
Home › Hologic, Inc. › Aptima Combo 2®

Aptima Combo 2®

Hologic, Inc. · Model KIT,APT. COMBO 2 (ROOM TEMP)CE · UDI-DI 15420045505353

MKZLSL Prescription
1
510(k) clearances
80
Adverse events
3
Recalls
22
Facilities

Description

Aptima Combo 2® Assay, 100 test, box 2 of 2 (15°C to 30°C box). The Aptima Combo 2® Assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal urogenital disease using the Tigris® DTS® Automated Analyzer or semi-automated instrumentation as specified.

Recalls

DateFirmReason
2010-09-29Becton Dickinson & Co.In vitro diagnostic reagent packs may be underfilled and contribute to invalid quality control testing or false positive patient results.
2009-09-18Becton Dickinson & Co.Product was shipped beyond its expiration date.
2004-07-07Roche Molecular Systems IncAn increased frequency of 'blue foci' that potentially can cause elevated A450 background in microwell plate wells after the addition of conjugate reagent during PCR detection.

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API keyRead the docs
Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.